First author | Year | Country | Sample size | Pathology | Neoadjuvant treatment schedule | Jadad score | |
---|---|---|---|---|---|---|---|
CRTS | SA | ||||||
Urba [12] | 2001 | USA | 50 | 50 | SCC (25%); AC (75%) | 45 Gy; 1.5 Gy per fraction over 3 weeks | 2 |
Two cycles: cisplatin 20 mg/m2 days 1–5; fluorouracil 300 mg/m2 days 1–21; vinblastine 1 mg/m2 days 1–4 | |||||||
An [13] | 2003 | China | 48 | 49 | SCC | 36 Gy, 1.2 Gy per fraction over 17 days | 3 |
First cycle: 5-fluorouracil 1 mg/m2, 5–6 hours, days 1–5; cisplatin 25 mg/m2. | |||||||
Second cycle: 5-fluorouracil 0.5 g/m2, days 21–25; cisplatin 25 mg/m2, days 22–25 | |||||||
Lee [14] | 2004 | Korea | 51 | 50 | SCC | 45.6 Gy, 1.2 Gy per fraction over 28 day | 2 |
Two cycles: cisplatin 60 mg/m2 days 1; fluorouracil 1000 mg/m2 days 3–5 | |||||||
Burmeister [15] | 2005 | Australia | 128 | 128 | SCC (37%); AC (62%) | 35 Gy in 15 fractions over 3 weeks | 3 |
One cycles: cisplatin 80 mg/m2 days 1; fluorouracil 800 mg/m2 days 1–4 | |||||||
Natsugoe [16] | 2006 | Japan | 22 | 23 | SCC | 40 Gy, 2 Gy per fraction over 4 weeks | 2 |
cisplatin 7 mg over 2 hours; 5-fluorouracil 350 mg over 24 hours | |||||||
Tepper [17] | 2008 | USA | 30 | 26 | SCC (25%); AC (75%) | 50.4 Gy, 1.8 Gy per fraction over 5.6 weeks | 3 |
Two cycles: cisplatin 100 mg/m2 days 1; fluorouracil 1000 mg/m2 per day days 1–4 | |||||||
Cao [18] | 2009 | China | 118 | 118 | SCC | 40 Gy, 2 Gy per fraction over 4 weeks | 2 |
cisplatin 20 mg/m2 per day days 1–5; fluorouracil 500 mg/m2 per day days 1–5; mitomycin 10 mg/m2 per day day 1 | |||||||
Hurmuzlu [19] | 2010 | Norway | 62 | 45 | SCC (36%); AC (64%) | 66 Gy, 2 Gy per fraction over 6.5 weeks | 3 |
Three cycles: cisplatin 100 mg/m2 days 1; fluorouracil 1000 mg/m2 per day days 1–5 | |||||||
Lv [20] | 2010 | China | 80 | 80 | SCC | 40 Gy, 2 Gy per fraction over 4 weeks | 2 |
Two cycles: cisplatin 20 mg/m2 per day, days 1–3, 22–25; | |||||||
paclitaxel 135 mg/m2 | |||||||
Saeki [24] | 2011 | Japan | 76 | 92 | SCC | 30-42 Gy , 1.8 Gy per fraction | 3 |
cisplatin: 5 mg/m2/day, 5-FU: 250 mg/m2/day, administered on weekdays, repeated every 3-4 weeks | |||||||
van Hagen [21] | 2012 | Netherlands | 168 | 186 | SCC (23%); AC (75%) | 41.4 Gy, 1.8 Gy per fraction over 4.6 weeks | 2 |
5 weeks chemotherapy: carboplatin area under curve =2 , paclitaxel 50 mg/m2 on day 1 weekly | |||||||
Fujiwara [22] | 2013 | Japan | 52 | 36 | SCC | 40 Gy, 2 Gy per fraction over 4 weeks | 3 |
5-FU (500 mg/m2/day), CDDP (15-20 mg/day), days 1-5, repeated every 3 weeks | |||||||
Smit [23] | 2013 | Italy | 75 | 75 | SCC | 41.4 Gy,1.8 Gy per fraction over 4.6 weeks | 3 |
5 weeks: paclitaxel (50 mg/m2), carboplatin (area under the curve = 2) |